About Ciberdem
Ciberdem: A Leading Research Center for Diabetes and Associated Metabolic Diseases
Ciberdem is a renowned research center that focuses on diabetes and associated metabolic diseases. The full name of the organization is "Centro de Investigación Biomédica en Red de Diabetes y Enfermedades Metabólicas Asociadas," which translates to "Biomedical Research Network Center for Diabetes and Associated Metabolic Diseases." Ciberdem is a network of researchers, scientists, clinicians, and healthcare professionals who work together to advance knowledge about diabetes and related conditions.
The mission of Ciberdem is to improve the prevention, diagnosis, treatment, and management of diabetes and associated metabolic diseases through innovative research. The organization aims to promote interdisciplinary collaboration among experts in various fields such as genetics, epidemiology, physiology, biochemistry, pharmacology, psychology, nutrition, exercise science, health economics, and public health. By integrating basic science with clinical practice and translational research with patient-centered outcomes research (PCOR), Ciberdem seeks to translate scientific discoveries into practical solutions that benefit patients with diabetes or at risk for developing it.
Ciberdem was established in 2006 as part of the Spanish Ministry of Science and Innovation's National Plan for Scientific Research Development and Technological Innovation.
Ciberdem has a multidisciplinary team of more than 200 researchers, including principal investigators, postdoctoral fellows, PhD students, research technicians, nurses, dietitians, psychologists, and administrative staff. The center is organized into six research programs that cover different aspects of diabetes and metabolic diseases:
1. Epidemiology and Prevention: This program focuses on identifying risk factors for diabetes and associated conditions in the general population or specific subgroups (e.g., children, adolescents, adults), developing strategies to prevent or delay the onset of these diseases through lifestyle interventions or pharmacological treatments.
2. Genetics and Epigenetics: This program aims to unravel the genetic basis of diabetes and related traits by studying DNA variations.
3. Pathophysiology: This program seeks to understand the mechanisms underlying insulin secretion and action in different tissues (e.g., pancreas, liver, muscle), as well as the interactions between metabolic pathways involved in glucose homeostasis (e.g., glycolysis/gluconeogenesis cycle). It also explores how inflammation and oxidative stress contribute to insulin resistance and beta-cell dysfunction.
4. Clinical Research: This program conducts clinical trials aimed at testing new therapies for diabetes or associated complications using rigorous methodology based on international standards such as Good Clinical Practice (GCP). It also performs observational studies that analyze real-world data from electronic health records (EHRs) or patient-reported outcomes (PROs).
5. Translational Research: This program bridges the gap between basic science discoveries and clinical applications by developing novel diagnostic tools, biomarkers, or therapeutic targets that can be translated into clinical practice. It also fosters collaborations with industry partners to accelerate the development of innovative therapies or medical devices.
6. Health Services Research: This program evaluates the impact of diabetes and associated conditions on healthcare systems and society as a whole by analyzing health outcomes, costs, and quality of life from different perspectives (e.g., patients, providers, payers). It also assesses the effectiveness and efficiency of healthcare interventions using economic evaluation methods such as cost-effectiveness analysis (CEA) or budget impact analysis (BIA).
Ciberdem has a strong commitment to education and dissemination of knowledge about diabetes and metabolic diseases. The center offers training programs for undergraduate students, graduate students, postdoctoral fellows, clinicians, nurses, dietitians, psychologists, and other professionals interested in pursuing a career in diabetes research or clinical practice. It also organizes scientific meetings such as workshops or symposia that bring together experts from different fields to share their latest findings and discuss future directions for research.
Ciberdem has received numerous awards and recognitions for its excellence in research. For example:
- In 2019 Ciberdem was awarded the "Severo Ochoa" accreditation by the Spanish Ministry of Science Innovation for its scientific quality.
- In 2020 Ciberdem was ranked among the top 10% institutions worldwide in diabetes research according to Scimago Institutions Rankings.
- In 2021 Ciberdem received funding from Horizon Europe program to develop a project on personalized medicine for T2D.
In conclusion,Ciberdem is an outstanding organization that plays a crucial role in advancing our understanding of diabetes mellitus type 1 (T1D), type 2 (T2D), gestational diabetes mellitus (GDM), obesity-related metabolic disorders , cardiovascular complications , microvascular complications autoimmune disorders ,and other related conditions through innovative research. Its multidisciplinary team of more than 200 researchers, six research programs, and strong commitment to education and dissemination make it a leading center in Europe for diabetes research.
ciberdem.org
